American Brain Tumor Association

2021 NATIONAL CONFERENCE
INFORM. EMPOWER. ENGAGE.
FRIDAY - SATURDAY SEPTEMBER 10 - 11, 2021
Welcome to the American Brain Tumor Association’s 28th Annual National Conference.

The ABTA National Conference is the largest brain tumor educational conference, specifically designed for patients, caregivers and survivors, across all ages and tumor types. Our goal is to provide access to our nation’s leading medical and research experts, and empower you with the information you need to navigate the physical and emotional journey of a brain tumor diagnosis for those newly diagnosed, experiencing a recurrence or in survivorship.

We have an exceptional program that will not only empower you with information about the latest advancements in treatments and research, but will also inspire you through the personal stories of patients and caregivers, and our Keynote speaker.

We are proud to welcome Courtney Burnett, MD, internal medicine physician, author, speaker and brain tumor survivor as the ABTA National Conference Keynote Speaker. Dr. Burnett, recently diagnosed with a malignant grade 3 anaplastic astrocytoma, will share how her experience transformed her thinking, and reshaped her approach to life, including how she found and spread joy with a “difficult gift,” a gift that teaches us, motivates us, changes us and inspires us.

I also want to recognize the leadership and dedication of our conference Co-Chairs, Shawn Hervey-Jumper, MD, FAANS, Associate Professor, Department of Neurological Surgery; Director, Glial Tumor Neuroplasticity Research Laboratory; and Co-Director of the Sheri Sobrato Brisson Brain Cancer Survivorship Program at University of California San Francisco, and Evanthia Galanis, MD, Professor of Oncology; Sandra J. Schulze Professor of Novel Therapeutics at Mayo Clinic. As nationally-recognized experts, they have designed a program that will provide you with the latest treatment advancements and care strategies to support all stages of a brain tumor diagnosis.

We look forward to spending time with you. Be sure to visit our website, abta.org, to learn more about patient, survivor and caregiver resources available to you. Learn about the many ways you can participate in the ABTA’s mission of advancing the understanding and treatment of brain tumors, with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis.

You continue to inspire us and move us forward in our mission.

Kind regards,

Ralph A. DeVitto
President & CEO
American Brain Tumor Association
Dear Conference Attendees,

Welcome to the American Brain Tumor Association 2021 National Conference, the largest educational program for brain tumor patients and caregivers. We recognize that the past year has been a challenge for many, and the COVID-19 pandemic has made in-person travel difficult. While we are not able to gather in person, we are pleased and excited to provide an outstanding program designed to inform, inspire and support you along your journey.

Session topics will discuss treatment advancements including neurosurgical advances and personalized medicine for a variety of brain tumors, clinical trials, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting is virtual, we are thrilled to engage with you and hope that you will do the same. We invite you to ask questions and share your experiences throughout the conference. As you can see from the agenda (on page 6), the conference includes other exciting opportunities to engage, including a variety of educational resources from our sponsors, research updates from ABTA-funded scientists, an opportunity to hear from patients and caregivers living with a brain tumor, and an interactive Social Hour, where you can engage with attendees from around the world. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We really look forward to spending time with you.

Sincerely, ABTA National Conference Co-Chairs

Shawn Hervey-Jumper, MD, FAANS &
Evanthia Galanis, MD
2021 ABTA National Conference
Co-Chairs

“Although the meeting is virtual, we are thrilled to engage with you and hope that you will do the same.”

Shawn Hervey-Jumper, MD, FAANS
Associate Professor, Department of Neurological Surgery
Director, Glial Tumor Neuroplasticity Research Laboratory
Co-Director of the Sheri Sobrato Brisson Brain Cancer Survivorship Program
University of California San Francisco

Evanthia Galanis, MD
Professor of Oncology,
Sandra J. Schulze Professor of Novel Therapeutics
Mayo Clinic
Chair, Neurooncology Committee,
Alliance for Clinical Trials in Oncology
Courtney is a 30-year-old internal medicine physician living and working in Saint Paul, Minn. Her brain tumor journey started unexpectedly in January 2020 when she was studying medicine in Thailand. While there, she began to have strange neurological symptoms and ended up diagnosing herself with a brain tumor. She returned to the United States, underwent two brain surgeries, and was eventually diagnosed with anaplastic astrocytoma, a grade 3 malignant brain tumor. Since her diagnosis, Courtney has completed standard of care treatment with both radiation therapy and oral chemotherapy. Fortunately, her treatment has been successful, and Courtney has been able to continue working full-time as a physician throughout her journey.

Additionally, Courtney started a blog on the first day of her diagnosis. Her blog, www.elephantlotusbraintumor.com, gained an unexpected worldwide following and readers encouraged her to write a book, so she did! Courtney has published many scientific papers, but her first memoir, *Difficult Gifts: A Physician’s Journey to Heal Body and Mind*, was published in February 2021.

“My brain tumor diagnosis was a “difficult gift,” a gift that teaches us, motivates us, changes us and inspires us.”

- Courtney Burnett, MD

Courtney is actively involved in advocacy and outreach. She continues to write and speak at national and international events about her journey to find happiness and live a meaningful life, despite an unexpected brain tumor diagnosis.
In 1994, Rick Sontag’s wife, Susan, was diagnosed and began treatment for a grade 3 astrocytoma, the most common form of glioma. In the time that followed, the family experienced firsthand the frustration of dealing with a disease that was not well understood by either the medical community or the general public.

In March 2002, Rick and Susan established The Sontag Foundation. Today, The Sontag Foundation is one of the largest private funders of brain cancer research in the United States. Since its inception, the foundation has funded over $40 million in grants for brain cancer research, as well as 51 grants to researchers at 34 institutions through its annual Distinguished Scientist Award. Twelve years later, Rick Sontag and The Sontag Foundation launched The Brain Tumor Network, Inc. (BTN), a nonprofit organization with the mission to aid adult patients with primary brain tumors who seek personalized information about treatment options beyond the standard of care.

Recently, in response to the COVID-19 pandemic, The Sontag Foundation announced “The Sontag Foundation COVID-19 Emergency Patient Assistance Fund” to provide financial support to patients affected with a brain tumor diagnosis or their caregivers who have been impacted by COVID-19.

Importantly, The Sontag Foundation and the ABTA has had a longtime partnership to expand our understanding of brain tumors through innovative research. In 2001 and 2002, the foundation donated a total $180,000 to ABTA’s research program. In 2003, the ABTA partnered with The Sontag Foundation and the James S. McDonnell Foundation, as well as other brain tumor organizations, to form the Brain Tumor Funder’s Collaborative (BTFC) to fund large brain tumor research projects that could not be funded individually.

More recently, the ABTA partnered with the Brain Tumor Network to help meet the expanding needs of brain tumor patients and families, by jointly referring them to each other’s services. In 2020, The Sontag Foundation was the ABTA’s first-ever presenting sponsor for the National Conference. And, in 2021, The Sontag Foundation provided a $50,000 matching grant that resulted in the funding of two ABTA Discovery Grants.

Since its founding in 2002, The Sontag Foundation has passionately supported people and organizations that make a significant and continuing impact in the lives of individuals with a major strategic focus on brain tumor research and support for patients with brain tumors.

About the Joel A. Gingras Award

Since 2011, the American Brain Tumor Association has awarded the Joel A. Gingras Jr. Award, our highest honor, to recognize an individual, organization or group that has made significant contributions to the Association’s mission through philanthropy, advocacy, discovery or patient care.
## PROGRAM AGENDA

### FRIDAY, SEPTEMBER 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
</table>
| 10:00 – 10:20 AM   | **WELCOME**                                                            | Ralph DeVitto, ABTA President & CEO  
Carla Varner, ABTA Board Chair  
Shawn Hervey-Jumper, MD, FAANS, University of California San Francisco, ABTA National Conference Chair  
Evanthia Galanis, MD, Mayo Clinic, ABTA National Conference Chair                                                                 |
| 10:20 – 10:50 AM   | **ABTA SESSION: WHO WE ARE, WHAT WE OFFER & HOW TO GET INVOLVED**       | Learn more about ABTA’s mission, which includes funding brain tumor research and providing invaluable resources and programs to patients, caregivers and families.  
Nicole Willmarth, PhD, ABTA Chief Mission Officer                                                                                           |
| 10:50 – 10:55 AM   | **BREAK & RESEARCH UPDATE**                                            | Precancer Mutations in Normal Brain: Implications for Oncogenesis and Diagnosis  
Javier Ganz, PhD, Boston Children’s Hospital                                                                                           |
| 10:55 – 11:40 AM   | **KNOW YOUR TUMOR**                                                    | Learn how brain tumors are diagnosed and how doctors use genetic markers to both classify tumors and predict outcome.  
Daniel J. Brat, MD, PhD, Northwestern University Feinberg School of Medicine                                                                 |
| 11:40 – 11:45 AM   | **BREAK & RESEARCH UPDATE**                                            | Tracing Extrachromosomal DNA Inheritance Patterns in Glioblastoma using CRISPR  
Eunhee Yi, PhD, The Jackson Laboratory for Genomic Medicine                                                                                   |
| 11:45 – 12:30 PM   | **NEUROSURGICAL ADVANCES**                                             | This session will inform attendees about the role of surgery to improve patient outcomes and how surgeons maximize safety and efficacy.  
Shawn Hervey-Jumper, MD, FAANS, University of California San Francisco, ABTA National Conference Chair  
Alfredo Quiñones-Hinojosa, MD, Mayo Clinic                                                                                           |
| 12:30 – 1:15 PM    | **LUNCH SESSION FEATURING:**                                           | Sponsors:  
Ivy Brain Tumor Center  
SonALAsense  
Cleveland Clinic  
Elekta                                                                                                                                         |
|                    | **Research Updates:**                                                   | Therapeutic Targeting of Endoplasmic Reticulum Proteostasis in GBM  
Christian Badr, PhD, Massachusetts General Hospital                                                                                           |
|                    |                                                                         | Synthetic Lethal Targeting of NAD(P)H-dependent DNA Damage in IDH Mutant Gliomas  
Odessa Yabut, PhD, University of California, San Francisco                                                                                   |
|                    |                                                                         | Tissue Factor as a Regulator of Receptor Tyrosine Kinases in Glioblastoma  
Anh Tran, PhD, Northwestern University                                                                                                         |
## PROGRAM AGENDA

**FRIDAY, SEPTEMBER 10**

### 12:30 – 1:15 PM CT

**LUNCH SESSION CONTINUED:**

**Sponsors:**
- GT Medical Technologies
- Monteris
- Cancer Treatment Centers of America
- Novocure
- Mayo Clinic
- Istari Oncology

### 1:15 – 2:00 PM CT

**PERSONALIZED MEDICINE & INDIVIDUALIZED TREATMENT**

Understand how genetic alterations in tumors can be used to create new personalized, patient-specific treatment options.

Ingo K. Mellinghoff, MD, FACP, *Memorial Sloan Kettering Cancer Center*

Priscilla Brastianos, MD, *Massachusetts General Hospital, Harvard Medical School*

### 2:00 – 2:05 PM CT

**BREAK & RESEARCH UPDATE**

**LXR Agonists Combined with BH3-mimetics as a Novel Treatment for Glioblastoma**

Thi Thu Trang Nguyen, PhD, *Columbia University*

### 2:05 – 3:15 PM CT

**BRAIN TUMOR BOARD**

Listen in as a multi-disciplinary panel of expert clinicians simulate the review of brain tumor cases to determine the best course of treatment for patients.

**Facilitator:**
- Mark R. Gilbert, MD, *Center for Cancer Research, National Cancer Institute, National Institutes of Health*

**Panelists:**
- **Neuro-Oncologist:**
  - Nancy Ann Oberheim Bush, MD, PhD, *University of California San Francisco*
- **Neurosurgeon:**
  - Alfredo Quiñones-Hinojosa, MD, *Mayo Clinic*
- **Radiation Oncologist:**
  - Ranjit S. Bindra, MD, PhD, *Yale School of Medicine*
- **Neuro-Pathologist:**
  - Daniel J. Brat, MD, PhD, *Northwestern University Feinberg School of Medicine*

### 3:15–3:20 PM CT

**BREAK & RESEARCH UPDATE**

A Vaccine Strategy to Overcome Treatment Induced Immunosuppression in Glioma

Maryam Rahman, MD, *University of Florida*

### 3:20 – 4:00 PM CT

**KEYNOTE SESSION: EMBRACING THE “DIFFICULT GIFTS” OF A BRAIN TUMOR**

Courtney Burnett, 30-year-old internal medicine physician, author, speaker and brain tumor survivor, shares her unexpected brain tumor diagnosis of a malignant grade 3 anaplastic astrocytoma. Hear how her experience transformed her thinking, and reshaped her approach to life, including how she found and spread joy with a “difficult gift,” a gift that teaches us, motivates us, changes us and inspires us.

Courtney Burnett, MD, *Internal Medicine Physician, Author and Brain Tumor Survivor*

### 4:00 – 4:10 PM CT

**CLOSING REMARKS**

Introductions by Carla Varner, ABTA Board Chair

Susan Kramer, ABTA Co-Founder, Honorary Board Member

### 4:10 – 5:00 PM CT

**ABTA SOCIAL HOUR**

Join a fun, interactive social hour with ABTA attendees from around the world! Get to know your fellow attendees by engaging in meaningful conversations in breakout rooms.
### PROGRAM AGENDA

**SATURDAY, SEPTEMBER 11**

<table>
<thead>
<tr>
<th>Time (CT)</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:10 AM</td>
<td><strong>WELCOME</strong></td>
</tr>
<tr>
<td></td>
<td>Ralph DeVitto, ABTA President &amp; CEO</td>
</tr>
<tr>
<td></td>
<td>Don and Gail Segal, ABTA Honorary Board Members</td>
</tr>
<tr>
<td>10:10 – 10:40 AM</td>
<td><strong>JOEL A. GINGRAS JR. AWARD PRESENTATION</strong></td>
</tr>
<tr>
<td></td>
<td>Introductions by Carla Varner, ABTA Board Chair</td>
</tr>
<tr>
<td></td>
<td>Johnathan Gingras, President, Joel A. Gingras, Jr. Memorial Foundation</td>
</tr>
<tr>
<td></td>
<td>Rick Sontag, President, The Sontag Foundation, The Brain Tumor Network and Spring Bay Companies</td>
</tr>
<tr>
<td>10:40 – 10:45 AM</td>
<td><strong>BREAK &amp; RESEARCH UPDATE</strong></td>
</tr>
<tr>
<td></td>
<td>A Novel Antimitotic in Glioblastoma</td>
</tr>
<tr>
<td></td>
<td>Morgan Schrock, DVM, PhD, Ohio State University</td>
</tr>
<tr>
<td>10:45 – 11:30 AM</td>
<td><strong>HOW TO NAVIGATE CLINICAL TRIALS</strong></td>
</tr>
<tr>
<td></td>
<td>Participation in clinical trials can offer patients and families access to novel brain tumor treatments. This session shares strategies in considering clinical trial enrollment.</td>
</tr>
<tr>
<td></td>
<td>John F. de Groot, MD, The University of Texas, MD Anderson Cancer Center</td>
</tr>
<tr>
<td></td>
<td>David A. Reardon, MD, Dana Farber Cancer Institute</td>
</tr>
<tr>
<td>11:30 – 11:35 AM</td>
<td><strong>BREAK &amp; RESEARCH UPDATE</strong></td>
</tr>
<tr>
<td></td>
<td>Immunosensing Glioblastoma Induced Glycomodulation</td>
</tr>
<tr>
<td></td>
<td>Lohitash Karumbaiah, PhD, University of Georgia</td>
</tr>
<tr>
<td>11:35 – 12:05 PM</td>
<td><strong>PATIENT NAVIGATION: GUIDING AND EMPOWERING PATIENTS AND CAREGIVERS</strong></td>
</tr>
<tr>
<td></td>
<td>Patient navigation is still considered a relatively new term in the health care industry, measured by metrics and tools. This session explores the positive impacts of Brain Tumor Navigation through the metric that matters most: the patient experience.</td>
</tr>
<tr>
<td></td>
<td>Tracy Edwards, MSW, LCSW, OSW-C, Brain Tumor Network</td>
</tr>
<tr>
<td></td>
<td>Jenna Tozzi, BA, RN, Brain Tumor Network</td>
</tr>
<tr>
<td>12:05 – 1:05 PM</td>
<td><strong>LUNCH SESSION FEATURING:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MEET THE ABTA BOARD OF DIRECTORS</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the ABTA Board of Directors and hear why they are involved with the ABTA.</td>
</tr>
<tr>
<td></td>
<td>Carla Varner, Chair</td>
</tr>
<tr>
<td></td>
<td>Ram Subramanian, Vice Chair, Chair of Mission Committee</td>
</tr>
<tr>
<td></td>
<td>Bob Kruchten, Treasurer, Chair of Finance and Audit Committee</td>
</tr>
<tr>
<td></td>
<td>Brandon Starkoff, Secretary</td>
</tr>
<tr>
<td></td>
<td>Jim Reilly, Immediate Past Chair</td>
</tr>
<tr>
<td></td>
<td>Mitch Berger, MD, Member</td>
</tr>
<tr>
<td></td>
<td>Jacqueline Lemke, Member (not in attendance)</td>
</tr>
<tr>
<td></td>
<td>Danny Monson, Member</td>
</tr>
<tr>
<td></td>
<td>Mindee Plugues, Member, Chair of Development Committee</td>
</tr>
<tr>
<td></td>
<td><strong>INTERNATIONAL LOW GRADe GLIOMA REGISTRY</strong></td>
</tr>
<tr>
<td></td>
<td>Elizabeth B. Claus, MD, PhD, Brigham and Women's Hospital, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td><strong>Sponsors:</strong></td>
</tr>
<tr>
<td></td>
<td>Northwestern Medicine</td>
</tr>
<tr>
<td></td>
<td>Gan &amp; Lee Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>University of Southern California</td>
</tr>
</tbody>
</table>

---

*Note: The meeting is virtual, but attendees are encouraged to participate.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:05 – 1:05 PM CT</td>
<td>LUNCH SESSION CONTINUED</td>
<td>Research Updates:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Impact of H3G34R Mutation in Reprogramming the Glioma Immune Microenvironment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maria Garcia Fabiani, PhD, University of Michigan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noninvasive Tools to Study Brain Metastasis Resistance to Immunotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Albert Kim, PhD, Massachusetts General Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immunological Determinants of Metastatic Colonization of Leptomeninges</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jan Remsik, PharmD, PhD, Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Sponsors:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Karyopharm Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fifth Season Financial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Navio</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NorthShore University HealthSystem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Society for Neuro-Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Miami Cancer Institute</td>
</tr>
<tr>
<td>1:05 – 1:50 PM CT</td>
<td>TREATMENT RESISTANCE</td>
<td>Learn about mechanisms of brain tumor resistance to drug treatment and strategies to overcome it.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ranjit S. Bindra, MD, PhD, Yale School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nancy Ann Oberheim Bush, MD, PhD, University of California San Francisco</td>
</tr>
<tr>
<td>1:50 – 1:55 PM CT</td>
<td>BREAK &amp; RESEARCH UPDATE</td>
<td>Bridging Innate and Adaptive GBM Immunity via Phagocytosis Checkpoint Blockade</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wen Jiang, MD, PhD, UT Southwestern Medical Center</td>
</tr>
<tr>
<td>1:55 – 2:40 PM CT</td>
<td>LOOKING TO IMMUNOTHERAPY TO MOVE FORWARD FROM RESISTANCE</td>
<td>Hear about innovative immuno-oncology approaches that can increase brain tumor responsiveness to immunotherapy strategies.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evanthia Galanis, MD, Mayo Clinic, ABTA National Conference Chair</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nino Chiocca, MD, PhD, Brigham And Women’s Hospital</td>
</tr>
<tr>
<td>2:40 – 2:45 PM CT</td>
<td>BREAK &amp; RESEARCH UPDATE</td>
<td>Theranostic Antibody for Improving Immunotherapy and Immune Monitoring in Glioma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gary Kohanbash, PhD, Children’s Hospital of Pittsburgh</td>
</tr>
<tr>
<td>2:45 – 3:30 PM CT</td>
<td>MANAGING MENTAL HEALTH AFTER A TUMOR DIAGNOSIS</td>
<td>Learn to manage distress during the brain tumor journey to enhance emotional well-being and extend quality survival.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ashlee R. Loughan, MEd, PhD, VCU School of Medicine</td>
</tr>
<tr>
<td>3:30 – 3:35 PM CT</td>
<td>BREAK &amp; RESEARCH UPDATE</td>
<td>Identifying Sex Differences in Intrinsic and Extrinsic Mechanisms in GBM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Justin Lathia, PhD, Cleveland Clinic</td>
</tr>
</tbody>
</table>
PROGRAM AGENDA

SATURDAY, SEPTEMBER 11

3:35 – 4:30 PM CT

LIVING WITH A BRAIN TUMOR: PATIENT AND CAREGIVER PANEL
Learn key strategies and approaches to navigate your brain tumor journey or that of your loved one in this lively and interactive brain tumor patient and caregiver panel addressing symptom management. Get ideas for how to cope and where to find resources and support.

Facilitator:
Heather E. Leeper, MD, MS, National Cancer Institute, National Institutes of Health

Patient and Caregiver Panelists:
Rick and Debbie Franzo
Natalie and Brandon Bir

4:30 PM – 4:40 PM CT

CLOSING COMMENTS & ADJOURNMENT
Carla Varner, ABTA Board Chair
Ralph DeVitto, ABTA President & CEO
**MAXIMIZING YOUR CONFERENCE EXPERIENCE**

Here are some tips to make the ABTA National Conference an enjoyable and educational experience. Registration is required to access presentations, sessions and ask questions with speakers. FREE registration at [www.abta.org/2021-national-conference](http://www.abta.org/2021-national-conference).

---

## GETTING THE MOST OUT OF THE CONFERENCE

1. Find a comfortable and quiet space to focus.
2. Plan to enter the conference 15 minutes before the first session to get familiar with navigating the virtual platform.
3. Plan ahead and choose the sessions you want to join in advance.
4. Have a notebook and pen handy to capture notes from each session.

---

## PRIOR TO THE CONFERENCE, DOWNLOAD AND CREATE A ZOOM ACCOUNT

We will be using Zoom as our virtual platform. Prior to the meeting, download the software and create an account to ensure a smooth virtual experience. You can download Zoom at [zoom.us/download](https://zoom.us/download).

---

## CONFERENCE LINK AND JOIN TIME

You will join the conference using the link/teleconference information provided a few days before the conference. Please join the Zoom meeting at least **15 minutes before** the program or session start time.

All presentations will take place in **Central Time Zone**.

---

## ASKING QUESTIONS DURING THE CONFERENCE

You will have an opportunity to submit questions anonymously throughout the program using the control panel on the bottom of your Zoom screen. Click on “Q&A” and type in your question. Our speakers will try to answer as many questions as time allows.

---

## PRESENTATION AUDIO/VIDEO

You will be able to hear and see presentations and the speakers during the conference. However, your own device audio and video will be muted throughout the conference. The only time you will have access to audio and video will be during the ABTA Social Hour.

---

## ENSURE A SMOOTH CONNECTION TO THE CONFERENCE

If using a desktop or laptop computer, connect your device to a hard-wired Internet connection (not Wi-Fi) and running at high-speed. Ensure all applications or any programs with notifications, pop-ups or reminders are closed (e.g., Outlook, chat, calendar applications).
Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
CONFERENCE CO-CHAIR GREETING

Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
Northwest Biotherapeutics is honored to participate in the American Brain Tumor Association's 2021 National Conference and invites you to visit our website for further information about our DCVax® Personalized Immune Therapies. Visit us on the web at www.nwbio.com.
At SDP Oncology we believe that purposeful science holds the potential to improve the lives of people with cancer.

SDP Oncology is proud to support the American Brain Tumor Association and its efforts to advocate for the brain tumor community.

Learn more at SDPOncology.com
Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
Dear Conference Attendees,

We want to give you our sincerest welcome to the American Brain Tumor Association 2020 National Conference. We recognize that the current situation prevents us from gathering together and we know that those who have participated in prior conferences share our disappointment in not being able to network in person. However, we are both pleased and excited to provide an outstanding program designed to inform and support you along your journey. Lecture topics will discuss treatment advancements for a variety of brain tumors, strategies to manage day-to-day symptoms and concerns, survivorship, emerging technologies, and much more.

Although the meeting will be virtual, we are encouraging you to be fully engaged. In that context, we invite you to ask questions and share your experiences throughout the conference. As you can see from the Program, the conference includes other invaluable experiences, including a variety of educational resources from our sponsors, poster presentations from our researchers, an opportunity to hear from patients and caregivers as they live with a brain tumor, and a Keynote speaker Maria Menounos, Emmy® Award-winning journalist, author, actress and brain tumor survivor. We hope this conference will be an invaluable and enriching experience.

Thank you so much for participating. We look forward to spending time with you.

Sincerely,

ABTA National Conference Co-Chairs
Mark R. Gilbert, MD and Jean Arzbaecher, RN, APN, CNRN
At Karyopharm Therapeutics, we’re in the fight to advance the treatment of patients with brain cancer.
The Ivy Brain Tumor Center is a nonprofit translational research program that offers the largest collection of Phase 0 clinical trials for brain tumor patients in the world.

Learn more at IvyBrainTumorCenter.org.
World-Class Care for Brain Tumors

At Northwestern Medicine, we combine innovative and compassionate care with a relentless search for cures, all to improve the lives of patients with cancer. Anchored by Northwestern Memorial Hospital, ranked No. 9 in the U.S. for Neurology and Neurosurgery, and No. 6 in the U.S. for Cancer care by U.S. News & World Report, 2021 - 2022, we offer access to the latest treatments and technology, including many pioneering brain tumor clinical trials downtown and in the suburbs. Each treatment plan is designed by a team of experts in medical oncology, radiation oncology, neuro-oncology, neurology, neurological surgery, neuropathology and neuroradiology, tailored to your needs and specific to the tumor to be treated.

Learn more at nm.org/braintumor.